Tags

Type your tag names separated by a space and hit enter

Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
J Am Acad Child Adolesc Psychiatry. 2002 Dec; 41(12):1431-8.JA

Abstract

OBJECTIVE

To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD).

METHOD

Between 1991 and 1998, 43 patients were randomly assigned to fluoxetine or placebo for 8 weeks. Dosing was fixed for the first 6 weeks (up to 60 mg/day) and then could be increased to 80 mg/day. Responders entered an 8-week maintenance phase. The primary outcome measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impression-Improvement (CGI-I) scale. Analyses were done on the intent-to-treat sample.

RESULTS

Fluoxetine patients (n = 21) had significantly lower CY-BOCS scores than placebo patients (n = 22) after 16 (but not 8) weeks. Fluoxetine responders (n = 11) had significantly lower CY-BOCS scores than placebo responders (n = 7) after an additional 8 weeks of treatment. After 16 weeks, 57% of fluoxetine (versus 27% of placebo) patients were much or very much improved on the CGI-I scale (p <.05). No patient terminated the study because of adverse medication effects.

CONCLUSION

Fluoxetine was well tolerated and effective for the treatment of child and adolescent OCD, but fluoxetine's full effect took more than 8 weeks to develop.

Authors+Show Affiliations

New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York 10032, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12447029

Citation

Liebowitz, Michael R., et al. "Fluoxetine in Children and Adolescents With OCD: a Placebo-controlled Trial." Journal of the American Academy of Child and Adolescent Psychiatry, vol. 41, no. 12, 2002, pp. 1431-8.
Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1431-8.
Liebowitz, M. R., Turner, S. M., Piacentini, J., Beidel, D. C., Clarvit, S. R., Davies, S. O., Graae, F., Jaffer, M., Lin, S. H., Sallee, F. R., Schmidt, A. B., & Simpson, H. B. (2002). Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41(12), 1431-8.
Liebowitz MR, et al. Fluoxetine in Children and Adolescents With OCD: a Placebo-controlled Trial. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1431-8. PubMed PMID: 12447029.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. AU - Liebowitz,Michael R, AU - Turner,Samuel M, AU - Piacentini,John, AU - Beidel,Deborah C, AU - Clarvit,Susan R, AU - Davies,Sharon O, AU - Graae,Flemming, AU - Jaffer,Margaret, AU - Lin,Shu-Hsing, AU - Sallee,Floyd R, AU - Schmidt,Andrew B, AU - Simpson,H Blair, PY - 2002/11/26/pubmed PY - 2003/1/11/medline PY - 2002/11/26/entrez SP - 1431 EP - 8 JF - Journal of the American Academy of Child and Adolescent Psychiatry JO - J Am Acad Child Adolesc Psychiatry VL - 41 IS - 12 N2 - OBJECTIVE: To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD). METHOD: Between 1991 and 1998, 43 patients were randomly assigned to fluoxetine or placebo for 8 weeks. Dosing was fixed for the first 6 weeks (up to 60 mg/day) and then could be increased to 80 mg/day. Responders entered an 8-week maintenance phase. The primary outcome measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impression-Improvement (CGI-I) scale. Analyses were done on the intent-to-treat sample. RESULTS: Fluoxetine patients (n = 21) had significantly lower CY-BOCS scores than placebo patients (n = 22) after 16 (but not 8) weeks. Fluoxetine responders (n = 11) had significantly lower CY-BOCS scores than placebo responders (n = 7) after an additional 8 weeks of treatment. After 16 weeks, 57% of fluoxetine (versus 27% of placebo) patients were much or very much improved on the CGI-I scale (p <.05). No patient terminated the study because of adverse medication effects. CONCLUSION: Fluoxetine was well tolerated and effective for the treatment of child and adolescent OCD, but fluoxetine's full effect took more than 8 weeks to develop. SN - 0890-8567 UR - https://www.unboundmedicine.com/medline/citation/12447029/Fluoxetine_in_children_and_adolescents_with_OCD:_a_placebo_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0890-8567(09)60737-1 DB - PRIME DP - Unbound Medicine ER -